Nabe T, Matsuya K, Akamizu K, Fujita M, Nakagawa T, Shioe M, Kida H, Takiguchi A, Wakamori H, Fujii M, Ishihara K, Akiba S, Mizutani N, Yoshino S, Chaplin D D
Department of Pharmacology, Kyoto Pharmaceutical University, Kyoto, Japan.
Br J Pharmacol. 2013 May;169(2):462-76. doi: 10.1111/bph.12154.
Mast cell hyperplasia has been observed in the lungs of mice with experimental asthma, but few reports have studied basophils. Here, we attempted to discriminate and quantify mast cells and basophils in the lungs in a murine asthma model, determine if both cells were increased by multiple antigen challenges and assess the roles of those cells in asthmatic responses.
Sensitized Balb/c mice were intratracheally challenged with ovalbumin four times. Mast cells and basophils in enzymatically digested lung tissue were detected by flow cytometry. An anti-FcεRI monoclonal antibody, MAR-1, was i.p. administered during the multiple challenges.
The numbers of both mast cells (IgE(+) C-kit(+) ) and basophils (IgE(+) C-kit(-) CD49b(+) ) increased in the lungs after three challenges. Treatment with MAR-1 completely abolished the increases; however, a late-phase increase in specific airway resistance (sRaw), and airway eosinophilia and neutrophilia were not affected by the treatment, although the early-phase increase in sRaw was suppressed. MAR-1 reduced antigen-induced airway IL-4 production. Basophils infiltrating the lung clearly produced IL-4 after antigen stimulation in vitro; however, histamine and murine mast cell protease 1 were not increased in the serum after the challenge, indicating that mast cell activation was not evoked.
Both mast cells and basophils infiltrated the lungs by multiple intratracheal antigen challenges in sensitized mice. Neither mast cells nor basophils were involved in late-phase airway obstruction, although early-phase obstruction was mediated by basophils. Targeting basophils in asthma therapy may be useful for an early asthmatic response.
在实验性哮喘小鼠的肺中观察到肥大细胞增生,但关于嗜碱性粒细胞的研究报道较少。在此,我们试图在小鼠哮喘模型中鉴别和定量肺中的肥大细胞和嗜碱性粒细胞,确定这两种细胞是否因多次抗原激发而增加,并评估这些细胞在哮喘反应中的作用。
用卵清蛋白对致敏的Balb/c小鼠进行4次气管内激发。通过流式细胞术检测酶消化肺组织中的肥大细胞和嗜碱性粒细胞。在多次激发期间腹腔注射抗FcεRI单克隆抗体MAR-1。
三次激发后,肺中肥大细胞(IgE(+) C-kit(+))和嗜碱性粒细胞(IgE(+) C-kit(-) CD49b(+))的数量均增加。用MAR-1治疗可完全消除这种增加;然而,特异性气道阻力(sRaw)的晚期增加以及气道嗜酸性粒细胞增多和嗜中性粒细胞增多不受该治疗影响,尽管sRaw的早期增加受到抑制。MAR-1可降低抗原诱导的气道IL-4产生。体外抗原刺激后,浸润肺的嗜碱性粒细胞明显产生IL-4;然而,激发后血清中的组胺和小鼠肥大细胞蛋白酶1并未增加,表明未诱发肥大细胞活化。
在致敏小鼠中,多次气管内抗原激发使肥大细胞和嗜碱性粒细胞均浸润到肺中。肥大细胞和嗜碱性粒细胞均未参与晚期气道阻塞,尽管早期阻塞由嗜碱性粒细胞介导。在哮喘治疗中靶向嗜碱性粒细胞可能对早期哮喘反应有用。